NVNO vs ANGO vs NVCR vs ATRC

For growth investors, AtriCure, Inc.

(ATRC) is the stronger pick with 14. 9% revenue growth year-over-year, versus -3. 8% for AngioDynamics, Inc. (ANGO). Analysts rate NovoCure Limited (NVCR) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, enVVeno Medical Corporation (NVNO) delivered a total return of +87.

9%, compared to -90. 2% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: ATRC returned +84. 4% versus NVNO's -92. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), AtriCure, Inc.

(ATRC) is the lower-risk stock at 0. 95β versus NovoCure Limited's 2. 15β — meaning NVCR is approximately 127% more volatile than ATRC relative to the S&P 500. On balance sheet safety, enVVeno Medical Corporation (NVNO) carries a lower debt/equity ratio of 3% versus 85% for NovoCure Limited — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), AtriCure, Inc.

(ATRC) is pulling ahead at 14. 9% versus -3. 8% for AngioDynamics, Inc. (ANGO). On earnings-per-share growth, the picture is similar: enVVeno Medical Corporation grew EPS 97. 9% year-over-year, compared to 21. 8% for NovoCure Limited. Over a 3-year CAGR, ATRC leads at 17. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

enVVeno Medical Corporation (NVNO) is the more profitable company, earning 0.

0% net margin versus -20. 8% for NovoCure Limited — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NVNO leads at 0. 0% versus -23. 5% for NVCR. At the gross margin level — before operating expenses — NVCR leads at 74. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for ATRC: 95.

3% to $51. 33.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, AtriCure, Inc.

(ATRC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 95)). enVVeno Medical Corporation (NVNO) carries a higher beta of 2. 02 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ATRC: +84. 4%, NVNO: -92. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.